Saturday, July 11, 2026
🇺🇸 FDA

pharma · NSCLC

Zibo Municipal Hospital

Zibo Municipal Hospital drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
1
Patents
0
All projects Drug pipeline News & analysis
Intelligence · Drug Pipeline

Zibo Municipal Hospital pipeline

Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Zibo Municipal Hospital drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

1 compounds

  1. tislelizumab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Zibo Municipal Hospital's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 inhibitor

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.